Bisoprolol: A review of its use in chronic heart failure

Drugs

Volumn 62, Issue 18, 2002, Pages 2677-2696

  McGavin, Jane K ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; RIFAMPICIN; THEOPHYLLINE; WARFARIN;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOMYOPATHY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FLU LIKE SYNDROME; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE VARIABILITY; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; MORTALITY; PNEUMONIA; REVIEW; SINUS BRADYCARDIA; STROKE; SURVIVAL; TACHYCARDIA; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; BISOPROLOL; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-1;

ANGINA;

EID: 0036954712     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262180-00017     Document Type: Review

References (55)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001 Dec; 38 (7): 2101-13
2. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001 Sep; 22 (17): 1527-60
3. Lancaster SG, Sorkin EM. Bisoprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs 1988 Sep; 36 (3): 256-85
4. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1- and beta2-adrenergic receptors. Cardiovasc Drugs Ther 1999 Apr; 13 (2): 123-6
5. Khan NUA, Movahed A. Role of β blockers in congestive heart failure. CHF 2000; 6: 299-312
6. Goldstein S. Benefits of β-blocker therapy for heart failure: weighing the evidence. Arch Intern Med 2002 Mar 25; 162: 641-8
7. Foody JM, Farrell MH, Krumholz HM. β-Blocker therapy in heart failure: scientific review. JAMA 2002 Feb 20; 287 (7): 883-9
8. Bouzamondo A, Hulot JS, Sanchez P, et al. Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 2001; 15: 95-109
9. Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol 1999 Oct; 22 (Suppl. V): 16-20
10. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994 Oct; 90 (4): 1765-73
11. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999 Jan 2; 353: 9-13
12. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997 Oct 7; 96 (7): 2197-205
13. Anthonio RL, Brouwer J, Lechat P, et al. Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). Am J Cardiol 1999 Apr 15; 83 (8): 1286-9, A10
14. Lechat P, Hulot J-S. Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001 Mar 13; 103 (10): 1428-33
15. Dubach P, Myers J, Bonetti P, et al. Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: analysis with magnetic resonance myocardial tagging. Am Heart J 2002 Apr; 143 (4): 676-83
16. Peng D-Q, Zhao S-P, Chen Y, et al. Effect of bisoprolol on QT dispersion in patients with congestive heart failure - the etiology-dependent response. Int J Cardiol 2001 Feb; 77 (2-3): 141-8; discussion 148-9
17. Nyolczas N, Dékány M, Fiók J, et al. Prediction of the effect of bisoprolol in dilated cardiomyopathy. Cardiovasc Drugs Ther 2000 Oct; 14 (5): 543-50
18. De Cree J, Van Nueten L, Geukens H, et al. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 1992; 12 (4): 159-63
19. Packer M. β-blockade in heart failure: basic concepts and clinical results. Am J Hypertens 1998 Jan; 11 (1 Pt. 2): 23S-37S
20. Pousset F, Copie X, Lechat P, et al. Effects of bisoprolol on heart rate variability in heart failure. Am J Cardiol 1996 Mar 15; 77 (8): 612-7
21. Copie X, Pousset F, Lechat P, et al. Effects of β-blockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. Am Heart J 1996 Aug; 132 (2 Pt. 1): 369-75
22. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001 Feb; 37 (2): 412-7
23. Olbinskaya L, Ignatenko S. Efficacy of bisoprolol, β1-selective adrenoblocker, in chronic heart failure patients with increased cytokine level [abstract no. 2703]. Eur Heart J 2002; 23 Suppl.: 514
24. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol 1986; 8 Suppl. 11: S16-20
25. Merck KGaA. Cardicor 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg film coated tablets: prescribing information [online]. Available from URL: http://www.emc.vhn.net/eMC/ [Accessed 2002 May 16]
26. Leopold G, Kutz K. Bisoprolol: pharmacokinetic profile. Rev Contemp Pharmacother 1997; 8: 35-43
27. Lewis R, Maclean D, Ioannides C, et al. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 1988 Jul; 26 (1): 53-9
28. Dixon MS, Thomas P, Sheridan DJ. A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. Eur J Clin Pharmacol 1990; 38 (1): 21-4
29. Dutta A, Lanc R, Begg E, et al. Dose proportionality of bisoprolol enantiomers in humans after oral administration of the racemate. J Clin Pharmacol 1994 Aug; 34 (8): 829-36
30. Le Coz F, Sauleman P, Poirier JM, et al. Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers. J Cardiovasc Pharmacol 1991 Jul; 18 (1): 28-34
31. Kirch W, Rose I, Klingmann I, et al. Interaction of bisoprolol with cimetidine and rifampicin. Eur J Clin Pharmacol 1986; 31: 59-62
32. Simon T, Mary-Krause M, Funck-Brentano C, et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001 Jan 23; 103 (3): 375-80
33. Simon T, Krause MM, Funck-Brentano C, et al. Bisoprolol dose-response in the Cardiac Insufficiency Bisoprolol Study (CIBIS II) [abstract]. 73rd Scientific Sessions of the American Heart Association; 2000 12-15 Nov; New Orleans (LA)
34. Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001 Aug; 3 (4): 469-79
35. Leizorovicz A, Lechat P, Cucherat M, et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies - CIBIS and CIBIS II. Am Heart J 2002 Feb; 143 (2): 301-7
36. Funck-Brentano C, Lancar R, Hansen S, et al. Predictors of medical events and of their competitive interactions in the Cardiac Insufficiency Bisoprolol Study 2 (CIBIS-2). Am Heart J 2001 Dec; 142 (6): 989-97
37. Funck-Brentano C, Lancar R, Le Heuzey J-Y, et al. Predictors of medical events in patients enrolled in the Cardiac Insufficiency Bisoprolol Study (CIBIS): a study of the interactions between beta-blocker therapy and occurrence of critical events using analysis of competitive risks. Am Heart J 2000 Feb; 139 (2 Pt. 1): 262-71
38. Schädlich PK, Paschen B, Brecht JG. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics 1998 Jan; 13 (1 Pt 2): 147-55
39. Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiovasc Drugs Ther 1998 Jul; 12 (3): 301-5
40. Varney S. A cost-effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001 Jun; 3 (3): 365-71
41. CIBIS-II Investigators and Health Economics Group. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J 2001 Jun; 22 (12): 1021-31
42. Malek M, Cunningham-Davis J, Malek L, et al. A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Int J Clin Pract 1999; 53 (1): 19-23
43. Ekman M, Zethraeus N. Jönsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 2001; 19 (9): 901-16
44. McMurray J, Cohen-Solal A, Dietz R, et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur J Heart Fail 2001; 3: 495-502
45. Aliot E, de Chillou C, Sadoul N. Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. Eur Heart J 2002; 4 (Suppl. D): D31-42
46. Wexler DJ, Chen J, Smith GL, et al. Predictors of costs of caring for elderly patients discharged with heart failure. Am Heart J 2001; 142 (2): 350-7
47. Owen A. Optimising the use of β-blockers in older patients with heart failure. Drugs Aging 2002; 19 (9): 671-84
48. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May 23; 334 (21): 1349-55
49. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 Jun 12; 353: 2001-7
50. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 2000 Mar 8; 283 (10): 1295-302
51. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1651-8
52. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001 May 5; 357: 1385-90
53. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001 May 31; 344 (22): 1659-67
54. Poole-Wilson P, Remme WJ. COMET: a multicentre randomised double-blind study to compare the effect of carvedilol and metoprolol on mortality and morbidity in patients with moderate or severe congestive heart failure (NYHA II-IV) [abstract no. 88]. Cardiovasc Drugs Ther 1999; 13: 24
55. Witte K, Thackray S, Clark AL, et al. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. Eur J Heart Fail 2000 Dec; 2 (4): 455-60